7-55191792-C-T
Variant summary
Our verdict is Likely benign. The variant received -3 ACMG points: 2P and 5B. PM1BP6BS1
The NM_005228.5(EGFR):c.2543C>T(p.Pro848Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000373 in 1,613,922 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. P848Q) has been classified as Uncertain significance.
Frequency
Consequence
NM_005228.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -3 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
EGFR | ENST00000275493.7 | c.2543C>T | p.Pro848Leu | missense_variant | Exon 21 of 28 | 1 | NM_005228.5 | ENSP00000275493.2 | ||
EGFR | ENST00000455089.5 | c.2408C>T | p.Pro803Leu | missense_variant | Exon 20 of 26 | 1 | ENSP00000415559.1 | |||
EGFR | ENST00000450046.2 | c.2384C>T | p.Pro795Leu | missense_variant | Exon 21 of 28 | 4 | ENSP00000413354.2 | |||
EGFR | ENST00000700145.1 | c.890C>T | p.Pro297Leu | missense_variant | Exon 8 of 9 | ENSP00000514824.1 |
Frequencies
GnomAD3 genomes AF: 0.000256 AC: 39AN: 152068Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.000358 AC: 90AN: 251310 AF XY: 0.000383 show subpopulations
GnomAD4 exome AF: 0.000385 AC: 563AN: 1461854Hom.: 0 Cov.: 31 AF XY: 0.000402 AC XY: 292AN XY: 727228 show subpopulations
GnomAD4 genome AF: 0.000256 AC: 39AN: 152068Hom.: 0 Cov.: 32 AF XY: 0.000229 AC XY: 17AN XY: 74266 show subpopulations
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:1
- -
- -
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in the germline of individuals with lung cancer, glioma, and retinoblastoma (Sequist 2006, Prim 2014, Akhavanfard 2021); Published functional studies demonstrate reduced/absent auto-phosphorylation, kinase activity, and capacity to bind c-Cbl (de Gunst 2007, Sarcar 2019); This variant is associated with the following publications: (PMID: 22848293, 17877814, 25176975, 16857818, 33326033, 31314158) -
not specified Uncertain:1Benign:1
DNA sequence analysis of the EGFR gene demonstrated a sequence change, c.2543C>T, in exon 21 that results in an amino acid change, p.Pro848Leu. This sequence change has been previously described in individuals with non-small cell lung cancer (NSCLC) (PMID: 25176975,16857818,22848293). In vitro functional studies have suggested that this variant is not a kinase activating mutation and showed a response to tyrosine kinase inhibitors, similar to the wild-type (PMID: 17877814, 22848293). This sequence change has been described in the gnomAD database with a frequency of 0.06% in the European subpopulation (dbSNP rs148934350). The p.Pro848Leu change affects a highly conserved amino acid residue located in a domain of the EGFR protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Pro848Leu substitution. Due to insufficient evidences and the lack of functional studies, the clinical significance of the p.Pro848Leu change remains unknown at this time. -
Pro848Leu variant in Exon 21 of EGFR: This variant is not expected to have clinical significance because iIn vitro studies suggest that this variant does not activate EGFR activity and does not render the protein sensitive to tyrosine kinase inhibitors (TKIs) (De Gunst 2007, Han 2011). It has been previously identified in both tumor and normal tissue in an individuals with lung cancer (Sequist 2007), and it has been identified in 0.06% (6/8600) of European American chromosomes by the NHLBI Exome Sequencing Project (http://evs.gs.washington.edu/EVS/; dbSNP rs148934350). -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
- -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Lung carcinoma Benign:1
- -
EGFR-related lung cancer Benign:1
- -
Lung cancer Other:1
Variant interpreted as Uncertain significance and reported on 11-11-2019 by Lab Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at